Osteo-Pharma BV announced today that it received formal notice that the European Patent Office’s Examining Division issued the formal notification of intention to grant the Osteo-Pharma patent application titled “Compositions and products for use in the treatment of bone fractures and defects”. The patent application, with application number 15750466.3, refers to formulations for medical devices or pharmaceuticals containing OsteoActivator that include coated collagen membranes for the treatment of orthopedic fractures or dental defects and OsteoActivator microspheres for the treatment of osteoarthritis or spinal compression fractures. "We are very pleased to announce this significant step which holds great promise for our company and our shareholders,” states Jan Gossen, Osteo-Pharma’s CEO. “This formal notification by the EPO is an essential first step in the final approval process”. In addition to Europe, Osteo-Pharma has submitted the patent application in several other territories, including the United States, China and Japan. About Osteo-Pharma: Osteo-Pharma, founded in 2014, is a Life Sciences company focused on the development of local treatments to improve the healing of bone fractures and defects. It’s proprietary OsteoActivator platform is used to develop coated biodegradable membranes, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in late stage pre-clinical development with various projects and anticipates initiating the first human clinical trial early 2019.
About Osteo-Pharma Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-late stage pre-clinical development with various projects and anticipates to initiate the first human clinical trials in the course of 2019.